iLite® ADCC Effector FcγRIIIa (V) Assay Ready Cells are used for quantifying biological activity induced by pathway activation of therapeutic antibody drugs in an ADCC mechanism of action (MOA) assay.
The cells are based on a human T lymphocyte cell line, Jurkat (ATCC #TIB-152), and have been genetically engineered and optimized to express high levels of the low affinity Fc receptor FcRyIIIa (CD16), and the Firefly Luciferase (FL) reporter gene under the control of a proprietary chimeric promoter.
iLite® ADCC Effector FcγRIIIa (V) Assay Ready Cells are ideally matched to the iLite® ADCC target cells but can be run with any type of target cells inducing ADCC MOA.
The ATCC® TIB-152 cell line is used under a license from ATCC®
FOR RESEARCH USE ONLY
|Size||1 vial corresponding to one 96 well plate|
|Read-out of results||Quantitative,|
|Regulatory status||Research Use Only|
>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium from Gibco (cat no 12648-010).
Get access to scientific material, posters and more.